RAC1 and neoplasm: Thus, the three drugs target signalling elements upstream of Rac1 and show acceptable tolerability in clinical studies in addition to anti‐neoplastic activity in different tumour types including advanced renal cell carcinoma, hepatocellular carcinoma and solid tumours.25, 26, 27